BOSTON and ROLLE, Switzerland, Aug. 28,
2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native
software company and a leader in data-driven medicine, today
announced presentations at the 22nd Annual Morgan
Stanley Healthcare Conference and the 9th Annual TD
Cowen FutureHealth Conference in early September.
Chief Financial Officer and Chief Operating Officer,
Ross Muken, will present at the
22nd Annual Morgan Stanley Healthcare Conference in
New York City on Wednesday, September 4, 2024, at 1:50 p.m. EDT.
The following week, co-Founder and Chief Executive Officer, Dr.
Jurgi Camblong, will join a Panel Discussion on AI in
Healthcare at the 9th Annual TD Cowen FutureHealth
Conference in New York City on
Tuesday, September 10, 2024, at
3:15 p.m. EDT.
The presentations will be webcast live on the SOPHiA
GENETICS Investor Relations website. Additionally, a replay will be
available on the website after its completion.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to deliver world-class care to patients with
cancer and rare disorders across the globe. It is the creator of
SOPHiA DDM™, a platform that analyzes complex genomic and
multimodal data and generates real-time, actionable insights for a
broad global network of hospital, laboratory, and biopharma
institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-to-present-at-the-22nd-annual-morgan-stanley-healthcare-conference-and-9th-annual-td-cowen-futurehealth-conference-302233232.html
SOURCE SOPHiA GENETICS